Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Remote monitoring can improve recovery from cancer surgery

2.

Radiation therapy can promote amphiregulin, which increases growth of metastases

3.

For cancer patients who are not responding to chemotherapy, new genes and natural toxins offer hope.

4.

DNA origami offers more accurate imaging in the fight against pancreatic cancer

5.

Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot